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Clinical  and  epidemiological  features  of multiple
myeloma patients  from a  low  socio-economic
region of  Brazil
Dear Editor,
Multiple myeloma (MM)  represents 1% of all new cases of
cancer worldwide.1 The International Myeloma  Foundation
estimates that about 30,000 MM  patients are currently under
treatment in Brazil. Since few studies have reported the clin-
ical and epidemiological features of MM in this country,2,3 we
aim to contribute to the clinical panorama of the disease by
describing a series of 65 patients (median age: 64 years; range:
35–80 years) diagnosed with MM between 2006 and 2014 at
the Hospital da LIGA (n = 55) and Oncoclínica São Marcos (n = 10),
Natal, RN. Patients diagnosed with monoclonal gammopa-
thy of undetermined signiﬁcance, asymptomatic MM,  POEMS
syndrome (polyneuropathy, organomegaly, endocrinopathy,
monoclonal gammopathy, and skin changes), solitary plasma-
cytoma, and primary plasma cell leukemia were excluded. The
majority of myeloma proteins were of the IgG isotype (69.2%).
The Kappa light chain was associated with the heavy chain
isotypes in 64.7% of cases. Most patients were in stage IIIA of
the Durie and Salmon (DS) classiﬁcation (80.4%) and in Stages
I, II and III of the International Staging System (ISS) (41.7%,
22.9% and 35.4%, respectively). Thirty-three patients (50.7%)
were submitted to conventional chemotherapy based on
cyclophosphamide, thalidomide and dexamethasone (CTD),
with 16 of them undergoing autologous hematopoietic stem
cell transplantations. Sixteen patients (24.6%) were treated
with a melphalan, prednisone and thalidomide (MPT) pro-
tocol. Eight (12.3%) patients were treated with thalidomide
with dexamethasone and eight (12.3%) with vincristine, dox-
orubicin and dexamethasone (VAD). Sixteen patients took
bortezomib as second line treatment after disease progres-
sion.
In our cohort, the clinical presentation and response
to treatment revealed gender-related differences not found
worldwide, with women being more  frequently affected than
men  (gender ratio M/F  = 0.6) and exhibiting lower creatinine
levels at diagnosis than men  (<1.3 mg/dL) (p-value = 0.032).
These epidemiological and clinical characteristics are notsimilar to the disease descriptions in the more  developed
southern regions of Brazil.2,3 In fact, in most countries, MM
is more  frequent in men  than in women.4,5 The causes of the
gender bias herein reported, whether related to referral (for
instance, due to women’s health campaigns which have been
intensiﬁed in Brazil over the last decades) or biological charac-
teristics of the population, are not evident and warrant further
studies. Regarding biological factors, Boyd et al.6 analyzed
cytogenetic alterations in a large MM cohort and suggested
that gender differences are inﬂuenced by the primary genetic
events, with immunoglobulin translocations being more  com-
mon in women and hyperdiploidy in men. In the southern
regions of Brazil, where genetic alterations have been studied
in MM,  no such bias was described.7
Plasmacytoma was deﬁned as bone and extramedullary
tumors that were identiﬁed upon physical examination and
by imaging studies, including a complete X-ray investigation,
computed tomography scan and magnetic resonance imaging.
Plasmacytoma was detected in 43.4% (23/53) of MM patients
at diagnosis. The thoracic curve of the vertebral column was
the most common site (40%), followed by the lumbar spine,
femur, skull and pelvis. The frequency of plasmacytoma was
higher than that reported worldwide,8,9 but similar to another
report from Brazil.10 Although not being considered a marker
of advanced disease or progression, since it can occur at any
stage of myeloma, plasmacytoma has been more  frequently
found in patients with higher tumor burden,9,10 which can
account for the increased incidence of plasmacytoma in our
study.
Overall (OS) and progression free survival (PFS) were 78%
and 50.9%, respectively. OS and PFS did not vary according
to ISS, DS staging or the presence of plasmacytoma (p-value
>0.5). Gender had an impact on OS with women having twice
the survival time as men  [mean time: 136 months; 95% con-
ﬁdence interval (95% CI): 10.2–116 months vs. 72 months;
95% CI 35–109 months, respectively – p-value = 0.005]. Low cal-
cium levels (less than and greater than or equal to 8 mg/dL)
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5% CI: 0–15 months vs. 37 months; 95% CI: 16–57 months
 p-value = 0.011) and OS (mean time: 16 months; 95% CI:
.1–21.8 months vs. 81 months; 95% CI: 24.5–137.4 months –
-value = 0.006).
We  acknowledge the limitation imposed by the reduced
umber of patients; however, our results in a particular series
f MM patients point to the need of improving strategies for
arly diagnosis and prognosis of MM in less privileged settings.
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